Table 2.

Demographic characteristics and functional follow-up parameters of Group 1 (management with only WJ-MSCs).

Patient no	Eye	BCVA		FPDI		ERG magnitude
		Time0	Time1	Time0	Time1	Time0	Time1
1	R	100	100	5	11	0.40	0.51
2	L	80	85	6	15	0.41	0.72
3	R	80	75	10	8	0.46	0.40
4	L	84	80	6	4	0.41	0.37
5	L	50	35	4	2	0.44	0.37
6	L	80	75	7	5	0.48	0.40
7	R	50	50	15	14	0.78	0.74
8	L	80	80	5	5	0.45	0.45
9	L	72	70	8	7	0.43	0.42
10	L	50	35	14	11	0.78	0.71
11	R	65	60	5	3	0.48	0.38
12	R	65	65	4	4	0.39	0.39
13	L	65	60	5	3	0.46	0.37
14	R	50	50	14	12	0.78	0.62
15	L	89	90	4	4	0.40	0.40
16	R	80	50	5	2	0.42	0.37
17	L	50	50	6	5	0.41	0.40
18	L	80	80	10	9	0.68	0.67
19	R	50	55	14	14	0.81	0.81
20	R	60	60	10	9	0.79	0.78
21	R	50	50	4	4	0.39	0.39
22	L	77	75	8	8	0.51	0.51
23	R	70	65	10	8	0.65	0.53
24	L	98	100	7	9	0.48	0.67
25	L	85	85	10	10	0.82	0.82
26	L	89	85	7	7	0.68	0.66
27	R	85	80	10	8	0.70	0.68
28	R	50	50	4	4	0.41	0.41
29	R	50	35	5	5	0.43	0.42
30	L	89	90	15	16	0.49	0.82
31	R	74	75	15	15	0.41	0.75
	L	80	80	14	14	0.41	0.72
32	R	60	50	8	5	0.45	0.37
	L	60	50	7	4	0.45	0.37

Time0 (baseline): just before the Wharton Jelly derived mesenchymal stem cell injection.

Time1: 36th month after injection.

Abbreviations: BCVA, best corrected visual acuity, (ETDRS letters); ERG magnitudes, full field flicker electroretinography magnitudes (mV); FPDI, fundus perimetry deviation index (%); WJ-MSCs, Wharton’s jelly derived mesenchymal stem cells.